Drug Profile
Research programme: CD26 antigen inhibitors - Novartis
Alternative Names: DDP-IV inhibitors - Novartis; Dipeptidyl peptidase IV inhbitors - novartis; PKF 275055Latest Information Update: 22 May 2012
Price :
$50
*
At a glance
- Originator Novartis
- Class Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic neuropathies
Most Recent Events
- 22 May 2012 No development reported - Preclinical for Diabetic neuropathies in Italy (PO)
- 01 Oct 2009 Preclinical trials in Diabetic neuropathies in Italy (PO)